Industry associations and companies in the United States, including the US Chamber of Commerce, Coalition of Services ...

The equity portion of the abrdn World Healthcare Fund fell (gross) but outperformed its custom benchmark over Q4 2024. Click ...

Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has entered into the Medicaid ...

Mesoblast’s RYONCIL ® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal ...

Democracy is under threat, but failure to deliver its benefits is the most likely reason for it to collapse. We need to take ...

Buy rating initiated! Discover why this medtech leader with strong growth prospects & dividends is worth your attention.